TD Private Client Wealth LLC Cuts Position in GSK plc (NYSE:GSK)

TD Private Client Wealth LLC trimmed its holdings in shares of GSK plc (NYSE:GSK) by 78.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,726 shares of the pharmaceutical company’s stock after selling 9,696 shares during the period. TD Private Client Wealth LLC’s holdings in GSK were worth $92,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Primecap Management Co. CA raised its stake in GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock valued at $854,349,000 after buying an additional 10,407,905 shares during the last quarter. FMR LLC increased its holdings in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Mondrian Investment Partners LTD raised its position in shares of GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock worth $205,920,000 after purchasing an additional 874,004 shares during the last quarter. Hotchkis & Wiley Capital Management LLC boosted its stake in GSK by 30.8% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares in the last quarter. Finally, Miller Howard Investments Inc. NY purchased a new stake in GSK during the 4th quarter valued at about $23,366,000. 15.74% of the stock is owned by institutional investors.

GSK Trading Up 0.2 %

NYSE:GSK opened at $38.65 on Wednesday. The company has a market cap of $80.00 billion, a PE ratio of 24.31, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. GSK plc has a 12 month low of $31.72 and a 12 month high of $45.93. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a 50 day simple moving average of $36.90 and a two-hundred day simple moving average of $36.80.

GSK (NYSE:GSK) last announced its earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts forecast that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a dividend of $0.3932 per share. This represents a $1.57 annualized dividend and a dividend yield of 4.07%. The ex-dividend date of this dividend is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. GSK’s dividend payout ratio (DPR) is currently 98.74%.

Analyst Upgrades and Downgrades

GSK has been the subject of several analyst reports. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating for the company. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.